Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase

Joshua J. Bornstein, Todd J. Eckroat, Jacob L. Houghton, Christopher K. Jones, Keith D. Green, Sylvie Garneau-Tsodikova

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Alzheimer's disease (AD) is a complex syndrome characterized by the degeneration of the brain and central nervous system that may be caused by an assortment of genetic and environmental factors. Consequently, a conjunctive approach targeting multiple affecters of AD could lead to improved drug candidates for the treatment of AD. A convergent chemical synthetic approach yielded a series of tacrine-mefenamic acid hybrids that were evaluated for their ability to inhibit acetylcholinesterase (AChE). A majority of the compounds tested showed low nanomolar IC50 values, an improvement over the parent compound, tacrine, suggesting that they could be effective in increasing cholinergic function. Additionally, an assay to evaluate the compounds upon exposure to reactive oxygen species was performed, the results of which may suggest a role for the mefenamic acid moiety in the inhibition of AChE. Molecular modeling studies were performed to rationalize the experimental results.

Original languageEnglish (US)
Pages (from-to)406-412
Number of pages7
JournalMedChemComm
Volume2
Issue number5
DOIs
StatePublished - May 1 2011

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase'. Together they form a unique fingerprint.

  • Cite this

    Bornstein, J. J., Eckroat, T. J., Houghton, J. L., Jones, C. K., Green, K. D., & Garneau-Tsodikova, S. (2011). Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase. MedChemComm, 2(5), 406-412. https://doi.org/10.1039/c0md00256a